US · BLRX · BIOTECHNOLOGY
BioLineRx Ltd. (BLRX) intrinsic value and stock valuation
$0.96as of 2026-11-21 · Mkt cap 11.82M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
BioLineRx Ltd. DCF and intrinsic value
InvestorsCraft values BLRX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from BLRX’s statements →
BioLineRx Ltd. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.19M | $28.9M | $4.8M | $0.00 | $0.00 |
| Operating income | -$-10.37M | -$-20.41M | -$-49.69M | -$-29.16M | -$-24.78M |
| Net income | -$-1.18M | -$-9.22M | -$-60.61M | -$-24.95M | -$-27.05M |
| EPSd | -$-287.1K | -$-4.61M | -$-37.65M | -$-19.34M | -$-24.59M |
| Operating cash flow | -$-8.14M | -$-43.87M | -$-22.61M | -$-26.24M | -$-23.57M |
| Capital expenditure | -$-30K | -$-50K | -$-300K | -$-320K | -$-100K |
| Free cash flow | -$-8.16M | -$-43.93M | -$-22.91M | -$-26.56M | -$-23.67M |
| Total assets | $40.9M | $38.9M | $63.9M | $76.4M | $81.4M |
| Total debt | $10.2M | $15M | $11.6M | $12.3M | $4.65M |
| Net debt | $6.9M | $4.6M | $7.34M | $1.74M | -$-8.34M |
| Total equity | $23.3M | $13.5M | $13.2M | $50.8M | $68.1M |
| Cash and short-term investments | $20.9M | $19.6M | $43M | $51.1M | $57.1M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.19M | $28.9M | $4.8M | $0.00 | $0.00 |
| Cost of revenue | $760K | $9.26M | $3.69M | $0.00 | $0.00 |
| Gross profit | $430K | $19.7M | $1.11M | $0.00 | $0.00 |
| Research and development expenses | $7.66M | $9.15M | $12.5M | $17.6M | $19.5M |
| Selling, general and administrative expenses | $3.14M | $28.5M | $31.2M | $11.5M | $5.27M |
| Other expenses | $0.00 | $2.4M | $7.05M | $0.00 | $40K |
| Operating expenses | $10.8M | $40.1M | $50.8M | $29.2M | $24.8M |
| Cost and expenses | $11.6M | $49.4M | $54.5M | $29.2M | $24.8M |
| Interest income | $1.13M | $1.83M | $2.01M | $690K | $560K |
| Interest expense | $1.29M | $9.16M | $2.17M | $2.16M | $980K |
| Depreciation and amortization | $530K | $4.07M | $1.38M | $650K | $700K |
| Ebitda | -$-220K | $3.92M | -$-57.09M | -$-22.14M | -$-25.37M |
| Operating income | -$-10.37M | -$-20.41M | -$-49.69M | -$-29.16M | -$-24.78M |
| Total other income/expenses, net | $8.33M | $11.2M | -$-10.92M | $4.21M | -$-2.28M |
| Income before tax | -$-2.04M | -$-9.22M | -$-60.61M | -$-24.95M | -$-27.05M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-1.18M | -$-9.22M | -$-60.61M | -$-24.95M | -$-27.05M |
| Weighted average shares outstanding | $4.11M | $2M | $1.61M | $1.29M | $1.1M |
| Weighted average diluted shares outstanding | $4.11M | $2M | $1.61M | $1.29M | $1.1M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $20.9M | $19.6M | $43M | $51.1M | $57.1M |
| Net receivables | $460K | $3.86M | $710K | $720K | $140K |
| Inventory | $2.15M | $3.15M | $1.95M | $200K | $130K |
| Total current assets | $23.7M | $27.1M | $47.2M | $52M | $57.4M |
| Property, plant and equipment, net | $860K | $1.35M | $1.89M | $2.5M | $2.28M |
| Goodwill and intangible assets | $16.4M | $10.5M | $14.9M | $21.9M | $21.7M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $17.2M | $11.8M | $16.7M | $24.4M | $24M |
| Total assets | $40.9M | $38.9M | $63.9M | $76.4M | $81.4M |
| Accounts payable | $3.49M | $5.58M | $10.9M | $6.97M | $5.57M |
| Short-term debt | $4.71M | $5M | $3.67M | $1.97M | $2.92M |
| Deferred revenue | $0.00 | $0.00 | $13M | $0.00 | $0.00 |
| Total current liabilities | $12.1M | $15.4M | $42.8M | $10.7M | $9.72M |
| Long-term debt | $5.44M | $10M | $7.92M | $10.4M | $1.73M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $5.44M | $10M | $19.9M | $14.9M | $3.58M |
| Capital lease obligations | $980K | $1.6M | $1.82M | $2.16M | $1.89M |
| Total liabilities | $17.6M | $25.5M | $50.7M | $25.5M | $13.3M |
| Common stock | $73.4M | $38.1M | $31.4M | $27.1M | $21.1M |
| Retained earnings | -$-401M | -$-399.83M | -$-390.61M | -$-329.99M | -$-305.04M |
| Accumulated other comprehensive income (loss) | $18.2M | $16.1M | $17M | $14.8M | $12.7M |
| Total equity | $23.3M | $13.5M | $13.2M | $50.8M | $68.1M |
| Total investments | $17.6M | $9.13M | $38.7M | $40.5M | $44.2M |
| Total debt | $10.2M | $15M | $11.6M | $12.3M | $4.65M |
| Net debt | $6.9M | $4.6M | $7.34M | $1.74M | -$-8.34M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-1.18M | -$-9.22M | -$-60.61M | -$-24.95M | -$-27.05M |
| Depreciation and amortization | $530K | $4.07M | $1.38M | $650K | $700K |
| Stock-based compensation | $0.00 | $1.14M | $2.32M | $2.25M | $1.5M |
| Change in working capital | $1.27M | -$-21.82M | $15.2M | $1.24M | -$-540K |
| Accounts receivable | $3.77M | -$-2.12M | -$-360K | $0.00 | $0.00 |
| Inventory | $1M | -$-1.19M | -$-1.95M | $0.00 | $0.00 |
| Accounts payable | -$-3.51M | $0.00 | $4.55M | $0.00 | $0.00 |
| Net cash provided by operating activities | -$-8.14M | -$-43.87M | -$-22.61M | -$-26.24M | -$-23.57M |
| Investments in property, plant and equipment | -$-30K | -$-50K | -$-120K | -$-320K | -$-100K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | -$0.00 | $40K |
| Net cash used for investing activities | -$-8.61M | $29.4M | $1.44M | $4.01M | -$-38.22M |
| Common stock issued | $14M | $16.4M | $14.1M | $14.4M | $50.4M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $8.95M | $20.7M | $15.1M | $20.4M | $57.8M |
| Net change in cash | -$-7.19M | $6.18M | -$-6.33M | -$-2.4M | -$-3.84M |
| Cash at end of period | $3.25M | $10.4M | $4.25M | $10.6M | $13M |
| Operating cash flow | -$-8.14M | -$-43.87M | -$-22.61M | -$-26.24M | -$-23.57M |
| Capital expenditure | -$-30K | -$-50K | -$-300K | -$-320K | -$-100K |
| Free cash flow | -$-8.16M | -$-43.93M | -$-22.91M | -$-26.56M | -$-23.67M |
Line items
Line items
Line items
About BioLineRx Ltd.
BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer. This compound is currently progressing through Phase 2 studies for metastatic pancreatic adenocarcinoma and Phase 1b trials for acute respiratory distress syndrome linked to COVID-19 and other viral infections. Additionally, Motixafortide is being investigated for its therapeutic potential in solid tumors and acute myeloid leukemia. The company's pipeline also includes AGI-134, an immuno-oncology agent presently undergoing Phase 1/2a clinical evaluations for various solid tumors. Furthermore, BioLineRx is advancing BL-5010, a custom-designed, proprietary pen-like device intended for the non-surgical removal of skin lesions. BioLineRx maintains strategic alliances, notably a collaboration with MSD in the domain of cancer immunotherapy, and an agreement with MD Anderson Cancer Center to explore Motixafortide combined with KEYTRUDA (pembrolizumab) for pancreatic cancer. They also have a licensing deal with Perrigo Company plc for the over-the-counter sale of BL-5010.
- CEO
- Philip A. Serlin
- Employees
- 22
- Beta
- 0.71
Explore
Frequently asked questions
What is the intrinsic value of BioLineRx Ltd. (BLRX)?
InvestorsCraft does not currently publish an intrinsic value for BLRX. How the IC value is calculated.
Is BLRX undervalued?
InvestorsCraft does not publish an undervaluation signal for BLRX at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.